Partha Basu: Guidance from IARC/WHO on validating HPV detection tests with lower valency
Partha Basu, Head of the Early Detection, Prevention, and Infections Branch at the International Agency for Research on Cancer/World Health Organization (IARC/WHO), shared a post on LinkedIn about a paper he co-authored with colleagues published in Journal of Medical Virology:
“Much-awaited guidance from an expert group convened by IARC – International Agency for Research on Cancer / World Health Organization to validate HPV detection tests with lower valency is published in the Journal of Medical Virology.
LMIC-adapted HPV tests with lower valency (targeting high-risk HPV types less than 13/14) are expected to improve the efficiency of screening programmes significantly, saving costs for the programmes.
IARC has collaborated with the Department of Biotechnology, Government of India, to apply the new validation criteria to evaluate four home-grown HPV tests in India. Results will be published soon.”
Authors: Arianis Tatiana Ramírez, Gary M. Clifford, Joakim Dillner, Louise Kuhn, Marc Arbyn, Neerja Bhatla, Nicolas Wentzensen, Peter Sasien, Priya Abraham, Mary Luz Rol, Maribel Almonte, Partha Basu.
More posts featuring Partha Basu.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023